Citations

Clear

168 citation(s) found for "Perlmutter, J".

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
Yee, Douglas , Symmans, W. Fraser , Albain, Kathy S. , Chen, Yunn-Yi, Krings, Gregor , Wei, Shi , Harada, Shuko , Datnow, Brian, Fadare, Oluwole , Klein, Molly, Chen, Beiyun, Adamson, Kathi, Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Magliocco, Anthony M., Feldman, Mike, Rendi, Mara H. , Sattar, Husain, Zeck, Jay , Ocal, Idris Tolgay, Tawfik, Ossama , LeBeau, Lauren, Sahoo, Sunati , Vinh, Tuyethoa N., Chien, A. Jo , Forero‐Torres, Andres , Stringer-Reasor, Erica , Ellis, Erin D. , Lu, Janice , Lang, Julie E. , Clark, Amy S. , Nanda, Rita , Northfelt, Donald W. , Khan, Qamar J. , Viscusi, Rebecca K., Euhus, David , Edmiston, Kirsten K., Kemmer, Kathleen, Park, John W., Liu, Minetta C. , Olopade, Olufunmilayo I. , Leyland‐Jones, Brian , Tripathy, Debasish , Moulder, Stacy L. , Schwab, Richard B. , Lo, Shelly S. , Beckwith, Heather , Haugen, Patricia, Veer, Laura J. van’t , Perlmutter, Jane , Melisko, Michelle , Wilson, Amy , Peterson, Garry , Buxton, Meredith , Paoloni, Melissa, Clennell, Julia L. , Hirst, Gillian L. , Singhrao, Ruby , Steeg, Katherine, Matthews, Jeffrey B. , Asare, Smita , Sanil, Ashish, Esserman, Laura J. , Berry, Donald A. , Tripathy, Debu , Ocal, Idris T, Olopade, Olufunmilayo I , Symmans, W Fraser , Esserman, Laura J , Hirst, Gillian L , Yee, Douglas , DeMichele, Angela , Yau, Christina , Isaacs, Claudine , Chen, Yunn‐Yi , Krings, Gregor, Pambuccian, Stefan E. , Wallace, Anne M. , Pusztai, Lajos , Boughey, Judy C. , Elias, Anthony , Han, Hyo S , Chui, Stephen Y., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Asare, Adam L. , Matthews, Jeffrey B., Berry, Scott

Mayo Clinic

JAMA Oncology | July 23, 2020 | Volume: 6 | Issue: 9 | Pages: 1355

10.1001/jamaoncol.2020.2535 | PMID 32701140 Get It

Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk
Yuan, Fangcheng , Hung, Rayjean J. , Walsh, Naomi , Wheeler, William , Song, Lei , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hartge, Patricia, Hassan, Manal M. , Holly, Elizabeth A. , Hoover, Robert N. , Kirsten, Holger , Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Ng, Kimmie , Oberg, Ann L. , Porta, Miquel , Rabe, Kari G. , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Thompson, Ian M. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Shi, Jianxin , Li, Donghui , Petersen, Gloria M. , Wolpin, Brian M. , Platz, Elizabeth A. , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Bamlet, William R , Brennan, Paul , Hackert, Thilo , Katzke, Verena , Kirsten, Holger , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Li, Donghui , Klein, Alison P , Stolzenberg-Solomon, Rachael , Chaffee, Kari G. , Hung, Rayjean J , Visvanathan, Kala , Yuan, Fangcheng , Murphy, Neil , Porta, Miquel , Real, Francisco X , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Zhang, Han , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Rosendahl, Jonas , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Silverman, Debra T. , Wang, Xiaoliang , Wilkens, Lynne R. , Yu, Kai , Duell, Eric J. , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Research | July 8, 2020 | Volume: 80 | Issue: 18 | Pages: 4004-4013

10.1158/0008-5472.can-20-0447 | PMID 32641412 Get It

Abstract Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (±500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values < 0.05 (0.0040, 0.0057, 0.011, and 3.4 × 10−6, respectively). After excluding the 20 PDAC susceptibility regions (±500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P = 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC. Significance: The joint effects of common variants in genomic regions containing susceptibility loci for inflammatory bowel disease and chronic pancreatitis are associated with PDAC and may provide insights to understanding pancreatic cancer etiology.
Genome-Wide Gene–Diabetes and Gene–Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia
Tang, Hongwei, Jiang, Lai , Arslan, Alan A. , Bracci, Paige M. , Brennan, Paul , Canzian, Federico , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Campa, Daniele , Childs, Erica J., Fuchs, Charles S. , Gaziano, J. Michael , Hartge, Patricia, Hassam, Manal H., Holly, Elizabeth A. , Hoover, Robert N. , Hung, Rayjean J. , Kurtz, Robert C. , Lee, I-Min, Ng, Kimmie , Oberg, Ann L. , Peters, Ulrike , Porta, Miquel , Rabe, Kari G. , Rothman, Nathaniel , Scélo, Ghislaine , Sesso, Howard D. , Thompson, Ian M. , Tjønneland, Anne , Trichopoulou, Antonia , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Jacobs, Eric J. , Petersen, Gloria M. , Wolpin, Brian M. , Chatterjee, Nilanjan , Li, Donghui , Arslan, Alan A , Brennan, Paul , Canzian, Federico , Bamlet, William R , Blackford, Amanda , Duell, Eric J , Hung, Rayjean J , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Orlow, Irene , Sesso, Howard D , Tjønneland, Anne , Wactawski-Wende, Jean , Yu, Herbert , Amundadottir, Laufey , Klein, Alison P , Li, Donghui , Chaffee, Kari G. , Visvanathan, Kala , Porta, Miquel , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Stolzenberg‐Solomon, Rachael Z. , Freeman, Laura E. Beane , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Bamlet, William R. , Chanock, Stephen Jacob , Duell, Eric J. , Goggins, Michael , Malats, Núria , Milne, Roger L. , Orlow, Irene , Rothman, Nathaniel , Silverman, Debra T. , Wilkens, Lynne R. , Yu, Kai , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Kraft, Peter , Wei, Peng

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 16, 2020 | Volume: 29 | Issue: 9 | Pages: 1784-1791

10.1158/1055-9965.epi-20-0275 | PMID 32546605 Get It

Abstract Background: Obesity and diabetes are major modifiable risk factors for pancreatic cancer. Interactions between genetic variants and diabetes/obesity have not previously been comprehensively investigated in pancreatic cancer at the genome-wide level. Methods: We conducted a gene–environment interaction (GxE) analysis including 8,255 cases and 11,900 controls from four pancreatic cancer genome-wide association study (GWAS) datasets (Pancreatic Cancer Cohort Consortium I–III and Pancreatic Cancer Case Control Consortium). Obesity (body mass index ≥30 kg/m2) and diabetes (duration ≥3 years) were the environmental variables of interest. Approximately 870,000 SNPs (minor allele frequency ≥0.005, genotyped in at least one dataset) were analyzed. Case–control (CC), case-only (CO), and joint-effect test methods were used for SNP-level GxE analysis. As a complementary approach, gene-based GxE analysis was also performed. Age, sex, study site, and principal components accounting for population substructure were included as covariates. Meta-analysis was applied to combine individual GWAS summary statistics. Results: No genome-wide significant interactions (departures from a log-additive odds model) with diabetes or obesity were detected at the SNP level by the CC or CO approaches. The joint-effect test detected numerous genome-wide significant GxE signals in the GWAS main effects top hit regions, but the significance diminished after adjusting for the GWAS top hits. In the gene-based analysis, a significant interaction of diabetes with variants in the FAM63A (family with sequence similarity 63 member A) gene (significance threshold P < 1.25 × 10−6) was observed in the meta-analysis (PGxE = 1.2 ×10−6, PJoint = 4.2 ×10−7). Conclusions: This analysis did not find significant GxE interactions at the SNP level but found one significant interaction with diabetes at the gene level. A larger sample size might unveil additional genetic factors via GxE scans. Impact: This study may contribute to discovering the mechanism of diabetes-associated pancreatic cancer.
Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer
Song, Honglin , Dicks, Ed , Intermaggio, Maria P., Chenevix‐Trench, Georgia , Bowtell, David D.L. , Traficante, Nadia , Group, AOCS, Hosking, Karen, Piskorz, Anna , Oudenhove, Elke Van , Doherty, J.A. , Rossing, Mary Anne, Duerst, Matthias, Dörk, Thilo , Bogdanova, Natalia , Moysich, Kirsten B. , Odunsi, Kunle , Ness, Roberta B., Lester, Jenny, Pujara, Miguel Angel, Cunningham, Julie M. , Hildebrandt, Michelle, Huff, Chad , Li, Donghui , Wu, Xifeng , Yu, Yao , Levine, Douglas A. , Schildkraut, Joellen M. , Riggan, Marjorie J. , Webb, Penelope M. , Group, OPAL Study, Jakubowska, Anna , Alsop, Jennifer , Harrington, Patricia, Chan, Isaac H Y , Menon, Usha , Pearce, Celeste Leigh, Wu, Anna H. , Fazio, Anna de , Kennedy, Catherine J. , Goode, Ellen L. , Ramus, Susan J. , Gayther, Simon A. , DeFazio, Anna , Cunningham, Julie, Vierkant, Robert, Huff, Chad , Cybulski, Cezary , Pharoah, Paul D P , Dörk, Thilo , Ramus, Susan J , Webb, Penelope M , Menon, Usha , Moysich, Kirsten , Kennedy, Catherine J , Jakubowska, Anna , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Traficante, Nadia , Bowtell, David D , Tyrer, Jonathan P. , Group, AOCS, Brenton, James D. , Goranova, Teodora , Harris, Holly R. , Modugno, Francesmary , Karlan, Beth Y. , Jensen, Allan , Kjær, Susanne K. , Høgdall, Estrid , Campbell, Ian , Lázaro, Conxi , Vierkant, Robert A. , Winham, Stacey J. , Permuth, Jennifer B. , Berchuck, Andrew , Cybulski, Cezary , Gronwald, Jacek , Lubiński, Jan , Pharoah, Paul D.P.

Mayo Clinic

Journal of Medical Genetics | June 16, 2020 | Volume: 58 | Issue: 5 | Pages: 305-313

10.1136/jmedgenet-2019-106739 | PMID 32546565 Get It

Purpose The known epithelial ovarian cancer (EOC) susceptibility genes account for less than 50% of the heritable risk of ovarian cancer suggesting that other susceptibility genes exist. The aim of this study was to evaluate the contribution to ovarian cancer susceptibility of rare deleterious germline variants in a set of candidate genes. Methods We sequenced the coding region of 54 candidate genes in 6385 invasive EOC cases and 6115 controls of broad European ancestry. Genes with an increased frequency of putative deleterious variants in cases versus controls were further examined in an independent set of 14 135 EOC cases and 28 655 controls from the Ovarian Cancer Association Consortium and the UK Biobank. For each gene, we estimated the EOC risks and evaluated associations between germline variant status and clinical characteristics. Results The ORs associated for high-grade serous ovarian cancer were 3.01 for PALB2 (95% CI 1.59 to 5.68; p=0.00068), 1.99 for POLK (95% CI 1.15 to 3.43; p=0.014) and 4.07 for SLX4 (95% CI 1.34 to 12.4; p=0.013). Deleterious mutations in FBXO10 were associated with a reduced risk of disease (OR 0.27, 95% CI 0.07 to 1.00, p=0.049). However, based on the Bayes false discovery probability, only the association for PALB2 in high-grade serous ovarian cancer is likely to represent a true positive. Conclusions We have found strong evidence that carriers of PALB2 deleterious mutations are at increased risk of high-grade serous ovarian cancer. Whether the magnitude of risk is sufficiently high to warrant the inclusion of PALB2 in cancer gene panels for ovarian cancer risk testing is unclear; much larger sample sizes will be needed to provide sufficiently precise estimates for clinical counselling.
Posttranslational Regulation of the Exon Skipping Machinery Controls Aberrant Splicing in Leukemia
Zhou, Yalu, Han, Cuijuan , Wang, Eric , Lorch, Adam H., Serafin, Valentina , Cho, Byoung-Kyu , Gutierrez-Diaz, Blanca T. , Calvo, Julien , Fang, Celestia, Khodadadi‐Jamayran, Alireza , Tabaglio, Tommaso , Marier, Christian, Kuchmiy, Anna , Sun, Limin , Yacu, George, Filip, Szymon K. , Jin, Qi , Takahashi, Yoh-hei, Amici, David R. , Rendleman, Emily J. , Rawat, Radhika , Paganin, Maddalena , Kandela, Irawati , Politanska, Yuliya , Palhais, Bruno , Vlierberghe, Pieter Van , Taghon, Tom , Aifantis, Iannis , Goo, Young Ah , Guccione, Ernesto , Heguy, Adriana , Tsirigos, Aristotelis , Wee, Keng Boon , Mishra, Rama K. , Pflumio, Françoise , Accordi, Benedetta , Ntziachristos, Panagiotis , Jin, Qi , Taghon, Tom , Goo, Young Ah , Tsirigos, Aristotelis , Basso, Giuseppe , Khodadadi-Jamayran, Alireza , Van Vlierberghe, Pieter , Gutierrez Diaz, Blanca , Cho, Byoung-Kyu , Han, Cuijuan , Serafin, Valentina , Jin, Qi , Takahashi, Yoh-Hei, Bresolin, Silvia , Zhang, Cheng , Li, Hu , Abdala‐Valencia, Hiam , Mendillo, Marc L. , Zhu, Ping, Basso, Giuseppe , Jin, Qi

Mayo Clinic

Cancer Discovery | May 22, 2020 | Volume: 10 | Issue: 9 | Pages: 1388-1409

10.1158/2159-8290.cd-19-1436 | PMID 32444465 Get It

Abstract Splicing alterations are common in diseases such as cancer, where mutations in splicing factor genes are frequently responsible for aberrant splicing. Here we present an alternative mechanism for splicing regulation in T-cell acute lymphoblastic leukemia (T-ALL) that involves posttranslational stabilization of the splicing machinery via deubiquitination. We demonstrate there are extensive exon skipping changes in disease, affecting proteasomal subunits, cell-cycle regulators, and the RNA machinery. We present that the serine/arginine-rich splicing factors (SRSF), controlling exon skipping, are critical for leukemia cell survival. The ubiquitin-specific peptidase 7 (USP7) regulates SRSF6 protein levels via active deubiquitination, and USP7 inhibition alters the exon skipping pattern and blocks T-ALL growth. The splicing inhibitor H3B-8800 affects splicing of proteasomal transcripts and proteasome activity and acts synergistically with proteasome inhibitors in inhibiting T-ALL growth. Our study provides the proof-of-principle for regulation of splicing factors via deubiquitination and suggests new therapeutic modalities in T-ALL. Significance: Our study provides a new proof-of-principle for posttranslational regulation of splicing factors independently of mutations in aggressive T-cell leukemia. It further suggests a new drug combination of splicing and proteasomal inhibitors, a concept that might apply to other diseases with or without mutations affecting the splicing machinery. This article is highlighted in the In This Issue feature, p. 1241
Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
Newitt, David C. , Harnish, Roy, Gibbs, Jessica , Jones, Ella F. , Wilmes, Lisa J., Joe, Bonnie N. , Campbell, Michael J. , Veer, Laura J. van’t , DiMichele, Angela, Berry, Donald A. , Albain, Kathy S. , Chien, A. Jo , Clark, Amy S. , Edmiston, Kirsten K., Ellis, Erin D. , Euhus, David , Han, Heather, Khan, Qamar J. , Lu, Janice , Mitri, Zaha, Nanda, Rita, Northfelt, Donald W. , Sanft, Tara, Stringer-Reasor, Erica , Viscusi, Rebecca K., Yung, Rachel L. , Melisko, Michelle , Perlmutter, Jane , Schwab, Richard B. , Asare, Smita , Yau, Julie E., Onishi, Natsuko , Li, Wen , Nguyen, Alex , Basu, Amrita B , Yee, Douglas , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Lang, Julie E. , Meisel, Jane Lowe , Sanft, Tara , Wallace, Anne M. , Rugo, Hope S. , Symmans, W. Fraser , Yau, Christina , Esserman, Laura J. , Hylton, Nola M.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: PD9-05-PD9-05

10.1158/1538-7445.sabcs19-pd9-05 Get It

Abstract Purpose In breast MRI, contrast enhancement of normal fibroglandular tissue is referred to as background parenchymal enhancement (BPE). Hormonal status significantly affects the degree of BPE, potentially due to the association with mammary vascularity and activity1-5. Studies have shown that BPE may be associated with breast cancer survival6, treatment response to neoadjuvant chemotherapy (NAC)7,8 and future breast cancer risk9. In most patients undergoing NAC, BPE is suppressed by the nonspecific anti-proliferative effects of chemotherapy on normal breast and/or ovary5,10. However, some patients exhibit equivalent or even stronger BPE post-NAC compared to pre-NAC. We hypothesized that non-suppressed BPE in post-NAC MRI may be associated with inferior treatment response. This study aimed to investigate the association between BPE suppression and treatment response as defined by pathologic complete response (pCR). Methods This study included patients with stage II/III breast cancer enrolled in the I-SPY 2 TRIAL being treated with standard NAC with or without investigational agents. The whole cohort was split into two subgroups based on hormone receptor status (HR+, n= 536; HR-, n=452). Patients underwent dynamic contrast enhanced MRIs at four time points during NAC: baseline (T0), after 3 weeks of the first regimen (T1), inter-regimen (T2), and pre-surgery (T3). Using in-house software, the contralateral breast parenchyma was automatically segmented for the entire breast volume. Quantitative BPE (qBPE) was calculated as the mean early (~150s post-contrast injection) percent enhancement of the central 50% of the axial slices. A breast radiologist reviewed all exams and excluded those where automated segmentation failed to accurately define tissue. For T1, T2 and T3, BPE was categorized based on the change from T0 as suppressed (qBPE < qBPE[T0]) or non-suppressed (qBPE ≥ qBPE[T0]). Chi-squared test was used to examine the association between BPE suppression and pCR, with p<0.05 considered statistically significant. Results HR+ cohort: pCR rates were lower for patients with non-suppressed BPE than those with suppressed BPE at every visit (T1-T3) (Table 1). The difference was statistically significant at T2 (p=0.04) and T3 (p=0.01). Table 1: HR+ cohortpCR rate (%)No. of pCR patientsNo. of non-pCR patientsTotal number of patientsP valueOverall22.8122414536BPE at T1suppressed23.6822663480.45non-suppressed20.532124156BPE at T2suppressed25.7972803770.04*non-suppressed16.01789106BPE at T3suppressed25.7982833810.01*non-suppressed12.5128496 HR- cohort: pCR rates were slightly lower for the non-suppressed BPE group, but no statistically significant association was found (Table 2). Table 2: HR- cohortpCR rate (%)No. of pCR patientsNo. of non-pCR patientsTotal number of patientsP valueOverall44.7202250452BPE at T1suppressed46.81411603010.66non-suppressed44.45265117BPE at T2suppressed48.81441512950.79non-suppressed47.3434891BPE at T3suppressed49.31461502960.94non-suppressed48.9434588 Conclusion In HR+ breast cancer, lack of BPE suppression may indicate inferior treatment response. The contrasting results in HR+ and HR- cohorts are noteworthy in terms of the possible relationship between suppression of normal mammary and ovarian activity and treatment response in HR+ cancer. Reference Radiographics 2014; 34: 234-47. Radiology 1997; 203: 137-44. Radiology 1997; 203: 145-9. Breast J 2005; 11: 236-41. AJR Am J Roentgenol 2015; 204: 669-73. Eur Radiol 2018; 28: 4705-16. Eur Radiol 2016; 26: 1590-6. Transl Oncol 2015; 8: 204-9. J Clin Oncol 2019; : JCO1800378. Radiology 2015; 277: 687-96. Citation Format: Natsuko Onishi, Wen Li, David C. Newitt, Roy Harnish, Jessica Gibbs, Ella F. Jones, Alex Nguyen, Lisa Wilmes, Bonnie N. Joe, Michael J. Campbell, Amrita Basu, Laura J. van’t Veer, Angela DiMichele, Douglas Yee, Donald A. Berry, Kathy S. Albain, Judy C. Boughey, A. Jo Chien, Amy S. Clark, Kirsten K. Edmiston, Anthony D. Elias, Erin D. Ellis, David M. Euhus, Heather S. Han, Claudine Isaacs, Qamar J. Khan, Julie E. Lang, Janice Lu, Jane L. Meisel, Zaha Mitri, Rita Nanda, Donald W. Northfelt, Tara Sanft, Erica Stringer-Reasor, Rebecca K. Viscusi, Anne M. Wallace, Rachel Yung, Michelle E. Melisko, Jane Perlmutter, Hope S. Rugo, Richard Schwab, W. Fraser Symmans, Smita M. Asare, Julie E. Yau, Christina Yau, Laura J. Esserman, Nola M. Hylton. Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD9-05.
Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial
Newitt, David C. , Gibbs, Jessica , Wilmes, Lisa J., Jones, Ella F. , Joe, Bonnie N. , Sit, Laura , Chien, A. Jo , Price, Elissa R. , Albain, Kathy S. , Kuritza, Theresa , Morley, Kevin , Brandt, Kathy R., Choudhery, Sadia, Clark, Amy S. , Rosen, Mark, Wolverton, Dulcy , Fountain, Kelly , Euhus, David , Han, Heather, Niell, Bethany L. , Drukteinis, Jennifer S. , Lu, Janice , Mitri, Zaha, Nanda, Rita , Northfelt, Donald W. , Sanft, Tara, Stringer-Reasor, Erica , Viscusi, Rebecca K., Yung, Rachel L. , Asare, Smita , Melisko, Michelle , Perlmutter, Jane , Schwab, Richard B. , Veer, Laura J. van’t , Berry, Donald A. , Abé, Hiroyuki , Sheth, Deepa , Edmiston, Kirsten K., Ellis, Erin D. , Ha, Richard , Wynn, Ralph, Crane, Erin P., Dillis, Charlotte, Nelson, Michael T. , Church, An , Khan, Qamar J. , Oh, Karen Y. , Jafarian, Neda, Bang, Dae Hee , Mullins, Christiane, Woodard, Stefanie , Ojeda-Fornier, Haydee, Sheth, Pulin , Hovanessian‐Larsen, Linda , Eghtedari, Mohammad , Spektor, Michael , Giurescu, Marina E., Newell, Mary S. , Cohen, Michael A. , Berman, Elise, Smith, William P. , Fitzpatrick, Kim, Borders, Marisa H. , Yang, Wei , Goudreau, Sally , Brown, Thelma, Li, Wen , Onishi, Natsuko , Yau, Christina , Boughey, Judy C. , McDonald, Elizabeth S. , Elias, Anthony , Lang, Julie E. , Meisel, Jane Lowe , Sanft, Tara , Wallace, Anne M. , Yee, Douglas , Rugo, Hope S. , Symmans, W. Fraser , DeMichele, Angela , Isaacs, Claudine , Zamora, Kathryn , Lehman, Constance Dobbins , Dogan, Basak E , Esserman, Laura J. , Hylton, Nola M.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: PD9-04-PD9-04

10.1158/1538-7445.sabcs19-pd9-04 Get It

Abstract Background: In an adaptive randomized trial, when new treatment combinations are being tested, it is important to be able to identify patients who are progressing on treatment so that they can be changed to a different therapeutic regimen. We know that even within the molecularly high risk patients in I-SPY 2, there is considerable variation in biology. In this study, we will present results of using MRI-calculated functional tumor volume (FTV) to identify tumor progression for each breast cancer subtype. Methods: Patients (n=990) enrolled in the I-SPY 2 TRIAL who were randomized to the graduated experimental drug arms or controls from 2010 to 2016 were analyzed. Four MRI exams were performed for each patient: pre-NAC (T0), after 3 weeks of NAC (T1), between regimens (T2), and post-NAC (T3). Functional tumor volume (FTV) was calculated at each exam by summing voxels meeting enhancement thresholds. Tumor progression at T1, T2 or T3 was identified by a positive FTV change relative to T0. Visual inspection was used to exclude false progression due to strong background parenchymal enhancement post-contrast, prominent vessels, motion, or insufficient image quality. pCR was defined as no invasive disease in the breast and lymph nodes. Negative predictive value for pCR was defined as:NPV=number of true non-pCRs / number of patients with MRI assessed tumor progressions, where “true non-pCRs” referred to patients who were non-pCRs at surgery and were assessed as progressors by MRI. The analysis was performed in the full cohort and in sub-cohorts defined by HR and HER2 statuses. Results: Out of 990 patients, 878 had pCR outcome data (pCR or non-pCR, pCR rate = 35%). Total and non-pCR numbers for each subtype, number of patients with tumor progression assessed by MRI at T1, T2, and T3, and NPVs, are shown in Table 1. In the full cohort, the NPV increased consistently over treatment, from T1 (NPV=83%) to T2 (93%), and to T3 (100%). The HER2+ cancer subtypes showed fewer MRI-assessed tumor progressions than HER2- subtypes: e.g. 10/209 (5%) vs. 108/669 (16%) at T1. NPV was 100% for HER2+ subtypes at T1 and T2 except for a single misclassification of a HR- tumor at T1. Only 6 tumor progressors, all HER2- were identified at T3, and all were confirmed at surgery as non-pCRs (NPV=100%). For HR+/HER2-, the NPV increased slightly from 89% at T1 to 91% at T2, while triple negative subtype had a more substantial increase, from 78% to 92%. Conclusions: Our study showed strong association between tumor progressors assessed by MRI with true non-pCRs after NAC. For HER2+ tumors, although MRI progressors are rare, they strongly indicate non-pCR at all treatment time points, while HER2- subtypes show more accurate results later in treatment. We are evaluating MRI change at 6 weeks to determine if that time point is sufficient to predict progressors. Table 1 MRI assessed tumor progression at different treatment time pointN/non-pCRs/%non-pCRMRI assessed tumor progressionT1 (after 3 weeks)T2 (inter-regimen)T3 (post-NAC)NNPV (%)NNPV (%)NNPV (%)Full cohort878/572/65%11883.14192.76100%HR+/HER2-344/280/81%4588.91190.93100%HR+/HER2+134/85/63%610021000N/AHR-/HER2+75/23/31%47521000N/Atriple negative325/184/57%6377.82692.33100% Citation Format: Wen Li, Natsuko Onishi, David C Newitt, Jessica Gibbs, Lisa J Wilmes, Ella F Jones, Bonnie N Joe, Laura S Sit, Christina Yau, A. Jo Chien, Elissa Price, Kathy S Albain, Theresa Kuritza, Kevin Morley, Judy C Boughey, Kathy Brandt, Sadia Choudhery, Amy S Clark, Mark Rosen, Elizabeth S McDonald, Anthony D Elias, Dulcy Wolverton, Kelly Fountain, David M Euhus, Heather S Han, Bethany Niell, Jennifer Drukteinis, Julie E Lang, Janice Lu, Jane L Meisel, Zaha Mitri, Rita Nanda, Donald W Northfelt, Tara Sanft, Erica Stringer-Reasor, Rebecca K Viscusi, Anne M Wallace, Douglas Yee, Rachel Yung, Smita M Asare, Michelle E Melisko, Jane Perlmutter, Hope S Rugo, Richard Schwab, W. Fraser Symmans, Laura J van't Veer, Donald A Berry, Angela DeMichele, Hiroyuki Abe, Deepa Sheth, Kirsten K Edmiston, Erin D Ellis, Richard Ha, Ralph Wynn, Erin P Crane, Charlotte Dillis, Michael Nelson, An Church, Claudine Isaacs, Qamar J Khan, Karen Y Oh, Neda Jafarian, Dae Hee Bang, Christiane Mullins, Stefanie Woodard, Kathryn W Zamora, Haydee Ojeda-Fornier, Pulin Sheth, Linda Hovanessian-Larsen, Mohammad Eghtedari, Michael Spektor, Marina Giurescu, Mary S Newell, Michael A Cohen, Elise Berman, Constance Lehman, William Smith, Kim Fitzpatrick, Marisa H Borders, Wei Yang, Basak Dogan, Sally Goudreau, Thelma Brown, Laura J Esserman, Nola M Hylton. Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD9-04.
Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
Li, Wen , Newitt, David C. , Harnish, Roy, Jones, Ella F. , Wilmes, Lisa J., Gibbs, Jessica , Price, Elissa R. , Joe, Bonnie N. , Chien, A. Jo , Berry, Donald A. , Albain, Kathy S. , Clark, Amy S. , Edmiston, Kirsten K., Ellis, Erin D. , Euhus, David , Han, Heather, Khan, Qamar J. , Lu, Janice , Mitri, Zaha, Nanda, Rita , Northfelt, Donald W. , Sanft, Tara, Stringer-Reasor, Erica , Viscusi, Rebecca K., Yung, Rachel L. , Melisko, Michelle , Perlmutter, Jane , Schwab, Richard J. , Veer, Laura J. van’t , Asare, Smita , Goudreau, Sally , Abé, Hiroyuki , Sheth, Deepa , Wolverton, Dulcy , Fountain, Kelly , Ha, Richard , Wynn, Ralph, Crane, Erin P., Dillis, Charlotte, Kuritza, Theresa , Morley, Kevin , Nelson, Michael T. , Church, An , Niell, Bethany L. , Drukteinis, Jennifer S. , Oh, Karen Y. , Jafarian, Neda, Brandt, Kathy R., Choudhery, Sadia, Bang, Dae Hee , Mullins, Christiane, Woodard, Stefanie , Ojeda-Fornier, Haydee, Eghedari, Mohammad, Sheth, Pulin , Hovanessian‐Larsen, Linda , Rosen, Mark, Spektor, Michael , Giurescu, Marina E., Newell, Mary S. , Cohen, Michael A. , Berman, Elise, Smith, William P. , Fitzpatrick, Kim, Borders, Marisa H. , Yang, Wei , Onishi, Natsuko , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Lang, Julie E. , Meisel, Jane Lowe , Sanft, Tara , Wallace, Anne M. , Yee, Douglas , Rugo, Hope S. , Schwab, Richard, Symmans, W. Fraser , Yau, Christina , DeMichele, Angela , Zamora, Kathryn , McDonald, Elizabeth S. , Lehman, Constance Dobbins , Dogan, Basak E , Esserman, Laura J. , Hylton, Nola M.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P6-02-01-P6-02-01

10.1158/1538-7445.sabcs19-p6-02-01 Get It

Abstract Background: Strong background parenchymal enhancement (BPE) may cause overestimation in tumor volume measured from dynamic contrast-enhanced (DCE) MRI, which may adversely affect the ability of MR tumor volume to predict treatment outcome for patients undergoing neoadjuvant chemotherapy (NAC). Specifically, an overestimation of tumor volume can result in misclassification of patients with complete pathologic response (pCR) as non-responders, leading to less confidence in MRI prediction. As well, overestimation of extent of disease might lead to more aggressive surgical therapy than necessary. This study investigated whether high BPE in the contralateral breast influences the predictive performance of MRI-measured functional tumor volume (FTV) for patients with locally advanced breast cancer undergoing NAC. Methods: patients (n=990) enrolled in the I-SPY 2 TRIAL who were randomized to the graduated experimental drug arms or controls from 2010 to 2016 were analyzed. Each patient had 4 MRI exams: pre-NAC (T0), after 3 weeks of NAC (T1), between NAC regimens (T2), and post-NAC (T3). FTV was calculated at each MRI exam by summing voxels meeting enhancement thresholds. Background parenchymal enhancement (BPE) in the contralateral breast was calculated automatically as mean percentage enhancement on the early (nominal 150sec post-contrast) image in the fibroglandular tissue segmented from 5 continuous axial slices centered in the inferior-to-superior stack. For each treatment time point, patients having both FTV and BPE measurements were included in the analysis. The area under the ROC curve (AUC) was estimated as the association between FTV and pCR at T1, T2, and T3. The analysis was conducted in the full patient cohort and in sub-cohorts defined by hormone receptor (HR) and HER2 status. In each patient cohort, a cut-off BPE value was selected to classify patients with high vs. low BPE by testing AUCs estimated with low-BPE patients reached maximum when the cut-off value varied from median to maximum in steps of 10%. Results: Out of 990 patients, 878 had pCR outcome data (pCR or non-pCR, pCR rate = 35%). Table 1 shows the number of patients, pCR rate, and AUC of FTV for predicting pCR using all patients available vs. a subset patients with low BPE (< BPE cut-off). In the full cohort, AUC increased slightly across all time points after patients with high BPE were removed. In the HR+/HER2- subtype, AUC increased at T1 after removal of cases with high BPE (0.65 vs. 0.71). For HR-/HER2+, AUC increased substantially after removal of high BPE cases (0.65 to 0.86 at T1, 0.71 to 0.87 at T2, and 0.71 to 0.89 at T3), with greater improvement at the early time point (T1) compared to later time points (T2 and T3). Only a slight improvement in the AUC was observed in the HR+/HER2+ and HR-/HER2- subtypes across all time points. Conclusions: High background parenchymal enhancement adversely affected the predictive performance of functional tumor volume measured by DCE-MRI, at early treatment time point for HR+/HER2- and across all time points for HR-/HER2+ cancer subtype. The adverse effect might be offset using subtype-optimized enhancement threshold in calculating functional tumor volume. Table 1 Effect of BPE on the prediction of pCR using FTV at various treatment time pointsT1T2T3npCR rateAUCBPE cut-offnpCR rateAUCBPE cut-offnpCR rateAUCBPE cut-offFullAll64734%0.662762334%0.701761134%0.6925Subset45334%0.6831133%0.7230534%0.72HR+/HER2-All26218%0.651924918%0.718225518%0.7519Subset13118%0.7124818%0.7120419%0.76HR+/HER2+All10636%0.642110538%0.62269634%0.7120Subset5332%0.668438%0.665740%0.73HR-/HER2+All5175%0.65204774%0.71204973%0.7116Subset3073%0.862871%0.872475%0.89HR-/HER2-All22842%0.682822243%0.751821143%0.6916Subset15940%0.7111137%0.7810540%0.75 Citation Format: Wen Li, Natsuko Onishi, David C Newitt, Roy Harnish, Ella F Jones, Lisa J Wilmes, Jessica Gibbs, Elissa Price, Bonnie N Joe, A. Jo Chien, Donald A Berry, Judy C Boughey, Kathy S Albain, Amy S Clark, Kirsten K Edmiston, Anthony D Elias, Erin D Ellis, David M Euhus, Heather S Han, Claudine Isaacs, Qamar J Khan, Julie E Lang, Janice Lu, Jane L Meisel, Zaha Mitri, Rita Nanda, Donald W Northfelt, Tara Sanft, Erica Stringer-Reasor, Rebecca K Viscusi, Anne M Wallace, Douglas Yee, Rachel Yung, Michelle E Melisko, Jane Perlmutter, Hope S Rugo, Richard Schwab, W. Fraser Symmans, Laura J van't Veer, Christina Yau, Smita M Asare, Angela DeMichele, Sally Goudreau, Hiroyuki Abe, Deepa Sheth, Dulcy Wolverton, Kelly Fountain, Richard Ha, Ralph Wynn, Erin P Crane, Charlotte Dillis, Theresa Kuritza, Kevin Morley, Michael Nelson, An Church, Bethany Niell, Jennifer Drukteinis, Karen Y Oh, Neda Jafarian, Kathy Brandt, Sadia Choudhery, Dae Hee Bang, Christiane Mullins, Stefanie Woodard, Kathryn W Zamora, Haydee Ojeda-Fornier, Mohammad Eghedari, Pulin Sheth, Linda Hovanessian-Larsen, Mark Rosen, Elizabeth S McDonald, Michael Spektor, Marina Giurescu, Mary S Newell, Michael A Cohen, Elise Berman, Constance Lehman, William Smith, Kim Fitzpatrick, Marisa H Borders, Wei Yang, Basak Dogan, Laura J Esserman, Nola M Hylton. The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-02-01.
Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial
Wulfkuhle, Julia , Asare, Smita , Hirst, Gillian L. , Sit, Laura , Perlmutter, Jane , Liu, Minetta C. , Berry, Donald A. , Petricoin, Emanuel F. , Veer, Laura van ‘t , Hirst, Gillian L , Wolf, Denise M. , Yau, Christina , Swigart, Lamorna Brown , Park, John , DeMichele, Angela , Yee, Douglas , Esserman, Laura J. , Veer, Laura J. van’t

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P4-10-02-P4-10-02

10.1158/1538-7445.sabcs19-p4-10-02 Get It

Abstract Background: A variety of investigational HER2-inhibitor agents/combinations have been tested in I-SPY 2, including neratinib (N), TDM1 combined with pertuzumab (P) (TDM1/P), and trastuzumab (H) combined with pertuzumab (H/P; prior to this combination becoming standard of care), all with trastuzumab as control (Ctr). All three experimental arms graduated, showing improved efficacy over control in one or more receptor subsets (HR+HER2+, HR-HER2+, or/and HER2+). Here we assess 10 biomarkers in the HER2, ER/PR, and proliferation pathways on multiple levels of resolution (expression, protein, phospho-protein) as predictors of response in these four arms, hypothesizing that highly HER2-activated, proliferative tumors may be more sensitive to HER2-inhibition than those that are more luminal and quiescent. Methods: 192 HER2+ patients were considered in this analysis: (31 Ctr, 65 N, 52 TDM1/P, and 44 H/P). 10 biomarkers relating to HER2, ER, or proliferation were evaluated from pre-treatment biopsies: HER2 IHC (n=145), 3 expression signatures (n=192), BluePrint subtype (n=192), and 5 protein/phospho-protein analytes by RPPA (n=175). Each biomarker was tested for association with pCR in the whole population and within each arm using a logistic model. This analysis was adjusted for HR status and treatment arm as covariates, and performed within receptor subtypes. This analysis does not adjust for multiplicities of other biomarkers. Results: In the population as a whole, HER2 and HER2-signaling biomarkers, evaluated at multiple levels of resolution: IHC, total-/phospho-protein by RPPA, and mRNA (HER2 amplicon module) - are highly correlated (rho=0.8 [0.65-0.92]). Higher HER2 levels and activity are associated with response: HER2 IHC 3+ status (LR p=0.00032), total quantitative ERBB2 protein by RPPA (LR p=5.4E-09), ERBB2 activation levels (LR p=6.58E-06 (pERBB2 (Y1248)) and 9.95E-06 (pEGFR Y1173)), and the ERBB2 amplicon expression signature (LR p=2.38E-08). In contrast, higher average ER/PR expression associates with non-response to HER2-targeted therapy (LR p=4.28E-08). Both HER2 and ER/PR signaling phenotypes are captured by BluePrint subtyping; and consistent with the individual pathway markers, tumors classified Luminal-type had a lower pCR rate relative to those classified as Her2-type (or Basal-type) (LR p=4.84E-11). These associations all retain significance in a model adjusting for HR status and treatment arm, and in the HR+HER2+ subset. In addition, we quantitatively assessed proliferation markers at the total protein (RPPA: Ki67), phospho-protein (pAURKA) and mRNA (proliferation signature Module11_Prolif) levels. All three proliferation biomarkers predict response overall; but this association is strongest within the HR+HER2+ subset (LR p=0.0012 (Module11_prolif), 0.0036 (pAURK), and 0.045 (Ki67)). None of the biomarkers tested were associated with response in the HR-HER2+ subset. Numbers are small within individual arms. Within the HR+HER2+ subtype, higher HER2 and lower ER/PR is observed in responders in all experimental arms; but the proliferation markers Module11_Prolif (LR p=0.0031) and Ki67 total protein (LR p=0.0029) are associated with response to TDM1/P but not H/P or N. Conclusion: High HER2 signaling at the expression, protein, and phospho-protein levels, and low ER signaling, all predict response to HER2-inhibition across treatment arms. Proliferation markers may be useful for prioritizing therapies in the HR+HER2+ subset. Citation Format: Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Smita M. Asare, Gillian L. Hirst, Laura Sit, Jane Perlmutter, I-SPY 2 TRIAL Consortium, Minetta Liu, John Park, Angela DeMichele, Douglas Yee, Don Berry, Laura Esserman, Emanuel Petricoin, Laura van t' Veer. HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-10-02.
Abstract P3-11-02: Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial
Lo, Shelly S. , Chien, A. Jo , Lu, Janice , Albain, Kathy S. , Stringer-Reasor, Erica , Clark, Amy S. , Ellis, Erin D. , Perlmutter, Jane , Schwab, Richard B. , Melisko, Michelle , Veer, Laura J. van’t , Wilson, Amy , Singhrao, Ruby , Asare, Smita , Sanil, Ashish, Berry, Donald A. , Helsten, Teresa L. , Yau, Christina , Kalinsky, Kevin M. , Elias, Anthony , Wallace, Anne M. , Lang, Julie E. , Boughey, Judy C. , Yee, Douglas , DeMichele, Angela , Isaacs, Claudine , Rugo, Hope S. , Hylton, Nola M. , Symmans, W. Fraser , Esserman, Laura J.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P3-11-02-P3-11-02

10.1158/1538-7445.sabcs19-p3-11-02 Get It

Abstract Background: I-SPY2 is a multicenter, phase 2 trial using response-adaptive randomization within biomarker subtypes to evaluate novel agents as neoadjuvant therapy for high-risk breast cancer. The primary endpoint is pathologic complete response (pCR) at surgery. The goal is to identify (graduate) regimens with ≥ 85% Bayesian predictive probability of success (i.e., demonstrating superiority to control) in a future 300-patient phase 3 1:1 randomized neoadjuvant trial with pCR endpoint within signatures defined by hormone-receptor (HR), HER2, and MammaPrint (MP) status. Regimens may leave the trial for futility (< 10% probability of success), maximum sample size accrual (with probability of success ≥ 10% and < 85%), or safety concerns as recommended by the independent DSMB. For HER2+ patients, the I-SPY2 control arm was 12 weekly cycles of paclitaxel+trastuzumab (TH, control) followed by doxorubicin/cyclophosphamide (AC) q2-3 weeks x4 and surgery. Patritumab is a fully human monoclonal antibody that inhibits HER3. In this experimental arm for HER2+ patients, patritumab was given q3w x 4 cycles (18mg/kg loading dose followed by 9mg/kg/dose) concurrent with paclitaxel and trastuzumab q1w x 12 weeks (PTH, treatment), followed by AC q2-3w. Methods: Women with tumors ≥ 2.5cm were eligible for screening. MP low/HR+ tumors were ineligible. MRI scans (baseline, 3 weeks after start of therapy, prior to AC, and prior to surgery) were used in a longitudinal statistical model to predict pCR for individual patients. Analysis was intention to treat. Patients who switched to non-protocol therapy count as non-pCR. Patients on treatment arm therapy at the time of arm closure are non-evaluable. Graduation potential was in 3 of 10 pre-defined signatures: all HER2+, HR-/HER2+, and HR+/HER2+. Results: The PTH regimen was stopped at the recommendation of the Safety Working Group and DSMB based on a safety event (bilateral sensorineural hearing loss, Gr 3) observed in one patient. At the time of arm closure, N=31 patients had received PTH treatment; 4 patients receiving PTH were changed to non-protocol therapy and removed from the analysis. The final estimated pCR report will consider 27 PTH and 31 TH as evaluable patients. Accrual was insufficient to assess graduation, however, there appears to be good signal in the HER2+HR- but not HER2+HR+ signatures. I-SPY 2 TRIAL Est. pCR at time of arm closureSignaturesPTH (Treatment)N= 31TH (Control)N = 31All (HER2+)0.40 (0.22 - 0.59), n=310.23 (0.09 - 0.37), n=31HR-/HER2+0.64 (0.36 - 0.91), n=110.30 (0.12 - 0.47), n=12HR+/HER2+0.28 (0.08 - 0.48), n=200.20 (0.06 - 0.34), n=19 HR+/HER2+0.28 (0.08 - 0.48), n=200.20 (0.06 - 0.34), n=19The patient who developed Gr3 sensorineural hearing loss 6 days after the 2nd patritumab (and 4th paclitaxel/trastuzumab) treatment, did not recover her hearing after patritumab was stopped, and also reported Gr3 vulvovaginal pain, vulvitis, and vaginal inflammation. Other gynecological symptoms in the PTH arm include: 1 pt with Gr1 vaginal hemorrhage, and 1 pt with Gr2 dyspareunia. There was a higher frequency of Gr3 hypokalaemia (12.5% vs. 3.2%). One pt in the PTH arm reported Gr3 small intestinal obstruction which resolved with conservative management. Conclusion: The I-SPY 2 study aims to assess the probability that investigational regimens will be successful in a phase 3 neoadjuvant trial; PTH was stopped due to safety concerns, although there was activity in the HER2+ HR- signature. This is the first report of Gr3 hearing loss associated with patritumab/paclitaxel/trastuzumab, and thus attribution is uncertain. Citation Format: Teresa L Helsten, Shelly S Lo, Christina Yau, Kevin Kalinsky, Anthony D Elias, Anne M Wallace, A. Jo Chien, Janice Lu, Julie E Lang, Kathy S Albain, Erica Stringer-Reasor, Amy S Clark, Judy C Boughey, Erin D Ellis, Douglas Yee, Angela DeMichele, Claudine Isaacs, Jane Perlmutter, Hope S Rugo, Richard Schwab, Nola M. Hylton, W. Fraser Symmans, Michelle E Melisko, Laura J van't Veer, Amy Wilson, Ruby Singhrao, Smita M Asare, Ashish Sanil, Donald A Berry, Laura J Esserman. Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-11-02.